Intrinsiqq
Isofol Medical AB logo

Isofol Medical AB Financials

ISOFOL.XSTO

Compare

All currency values in kr millions unless otherwise noted

Scroll

Showing 6 of 7 available years
Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenuekr 0kr 0kr 0kr 1kr 13kr 22
Total Operating Expenses––––kr 180kr 227
Operating Income-kr 59-kr 56-kr 47-kr 42-kr 167-kr 204
Non-Operating
Net Interest Expense-kr 0-kr 0kr 0kr 0-kr 0-kr 0
Other Non-Operating Income (Expense)––––kr 8kr 4
EBT (Earnings Before Tax)––––-kr 160-kr 200
Income Tax Expensekr 0kr 0kr 0kr 0kr 0kr 0
Earnings from Continuing Ops––––-kr 160-kr 200
Net Income
Net Income-kr 57-kr 54-kr 43-kr 37-kr 160-kr 200
Per Share Data
Revenue Per Sharekr 0.00kr 0.00kr 0.00kr 0.00kr 0.08kr 0.18
EPS (Basic)-kr 0.20-kr 0.25-kr 0.24-kr 0.23-kr 0.99-kr 1.59
EPS (Diluted)-kr 0.20-kr 0.25-kr 0.24-kr 0.23-kr 0.99-kr 1.59
Shares Outstanding320.5M217.2M183.8M161.5M161.4M125.9M

Isofol Medical AB (ISOFOL.XSTO) financials: revenue, profit and margins

Isofol Medical AB (ISOFOL.XSTO) generated about SEK 0.00 in revenue and -SEK 57 million in net income over the trailing twelve months, growing at roughly -73.1% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Isofol Medical AB's (ISOFOL.XSTO) revenue?+

Isofol Medical AB generated about SEK 0.00 in revenue over the trailing twelve months. Revenue has grown at roughly -73.1% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Isofol Medical AB profitable?+

Isofol Medical AB reported about -SEK 57 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How fast is Isofol Medical AB growing?+

Isofol Medical AB's revenue has compounded at roughly -73.1% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside ISOFOL.XSTO's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with ISOFOL.XSTO

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
NXTCL.XSTONextCell Pharma AB
€0.01+18.52%50
KDEV.XSTOKDventures AB
kr 0.14+6.06%25
BIOSGN.XSTOBiosergen AB
No recent price20
HEART.XSTOScandinavian Real Heart AB
€1.28-0.39%10
2CUREX.XSTO2cureX AB
No recent price10
APOTEA.XSTOApotea AB
€9.00-0.94%71
XVIVO.XSTOXVIVO Perfusion AB
kr 197.15+1.00%44

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ISOFOL.XSTO

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.